BioXcel Therapeutics (BTAI) Short Interest Ratio & Short Volume $1.97 +0.16 (+8.84%) Closing price 04:00 PM EasternExtended Trading$1.93 -0.04 (-1.83%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BioXcel Therapeutics Short Interest DataBioXcel Therapeutics (BTAI) has a short interest of 317,600 shares, representing 5.74% of the float (the number of shares available for trading by the public). This marks a -38.41% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.3, indicating that it would take 1.3 days of the average trading volume of 1.22 million shares to cover all short positions.Current Short Interest317,600 sharesPrevious Short Interest515,700 sharesChange Vs. Previous Month-38.41%Dollar Volume Sold Short$495.46 thousandShort Interest Ratio1.3 Days to CoverLast Record DateJune 15, 2025Outstanding Shares6,060,000 sharesFloat Size5,530,000 sharesShort Percent of Float5.74%Today's Trading Volume280,554 sharesAverage Trading Volume1,218,914 sharesToday's Volume Vs. Average23% Short Selling BioXcel Therapeutics? Sign up to receive the latest short interest report for BioXcel Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBTAI Short Interest Over TimeBTAI Days to Cover Over TimeBTAI Percentage of Float Shorted Over Time BioXcel Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/2025317,600 shares $495.46 thousand -38.4%5.7%1.3 $1.56 5/31/2025515,700 shares $608.53 thousand +285.4%9.3%1.5 $1.18 5/15/2025133,800 shares $195.35 thousand +52.1%2.4%0 $1.46 4/30/202588,000 shares $162.80 thousand +18.4%1.9%0 $1.85 4/15/202574,300 shares $135.23 thousand -66.6%1.6%0 $1.82 3/31/2025222,700 shares $452.08 thousand +0.6%4.9%0.1 $2.03 3/15/2025221,300 shares $471.37 thousand -33.0%8.1%0.1 $2.13 2/28/2025330,500 shares $713.88 thousand +16.2%12.1%0.1 $2.16 2/15/2025284,500 shares $657.20 thousand +13.5%11.0%2 $2.31 1/31/2025250,700 shares $1.31 million -84.3%9.7%2.1 $5.22 Get the Latest News and Ratings for BTAI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20251,600,000 shares $554.40 thousand +98.1%N/A1.1 $0.35 12/31/2024807,700 shares $302.00 thousand -23.1%N/A1 $0.37 12/15/20241,050,000 shares $432.71 thousand +16.8%N/A1.7 $0.41 11/30/2024898,700 shares $367.30 thousand +44.0%N/A1.4 $0.41 11/15/2024624,100 shares $354.68 thousand +79.8%N/A1.2 $0.57 10/31/2024347,100 shares $231.45 thousand -39.8%N/A0.7 $0.67 10/15/2024576,400 shares $327.91 thousand +11.6%N/A1.2 $0.57 9/30/2024516,400 shares $315.00 thousand -26.0%N/A0.9 $0.61 9/15/2024697,600 shares $474.37 thousand +2.5%N/A1.1 $0.68 8/31/2024680,500 shares $418.51 thousand -6.9%N/A1.2 $0.62 8/15/2024731,200 shares $497.22 thousand -9.4%N/A1.2 $0.68 7/31/2024807,300 shares $904.18 thousand +28.9%N/A1.2 $1.12 7/15/2024626,100 shares $763.84 thousand -61.4%N/A1 $1.22 6/30/20241,620,000 shares $2.07 million +8.7%N/A2.8 $1.28 6/15/20241,490,000 shares $2.04 million +0.7%N/A2.9 $1.37 5/31/20241,480,000 shares $2.68 million -9.2%N/A2.6 $1.81 5/15/20241,630,000 shares $3.36 million +8.7%N/A2.8 $2.06 4/30/20241,500,000 shares $3.78 million -28.2%N/A1 $2.52 4/15/20242,090,000 shares $5.75 million -16.1%N/A1.4 $2.75 3/31/20242,490,000 shares $7.02 million -20.7%10.5%1.7 $2.82 3/15/20243,140,000 shares $8.42 million -20.9%14.6%2.1 $2.68 2/29/20243,970,000 shares $12.62 million -46.8%18.7%2.6 $3.18 2/15/20247,460,000 shares $26.78 million +203.3%35.2%4.9 $3.59 1/31/20242,460,000 shares $7.92 million -17.5%11.9%2.1 $3.22 1/15/20242,980,000 shares $7.84 million +0.3%14.4%1.1 $2.63 12/31/20232,970,000 shares $8.76 million +3.5%14.7%1 $2.95 12/15/20232,870,000 shares $9.30 million -16.6%14.2%0.9 $3.24 11/30/20233,440,000 shares $13.07 million -32.3%17.0%1.1 $3.80 11/15/20235,080,000 shares $22.35 million -12.6%25.1%1.6 $4.40 10/31/20235,810,000 shares $23.33 million +16.9%28.8%1.9 $4.02The mainstream media is wrong about AI — again (Ad)The mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And the media jumped to hasty conclusions. But as usual, there's one huge thing they missed.Click here to learn what everyone else missed. 10/15/20234,970,000 shares $15.56 million +38.8%24.6%3.6 $3.13 9/30/20233,580,000 shares $9.06 million -24.6%17.7%2.4 $2.53 9/15/20234,750,000 shares $15.87 million +8.0%23.5%1.6 $3.34 8/31/20234,400,000 shares $16.63 million -34.8%21.8%1.5 $3.78 8/15/20236,750,000 shares $27.95 million -4.1%33.5%2.3 $4.14 7/31/20237,040,000 shares $64.35 million -18.8%35.0%2.7 $9.14 7/15/20238,670,000 shares $89.30 million +69.0%43.1%3.5 $10.30 6/30/20235,130,000 shares $34.17 million +12.3%25.5%2.2 $6.66 6/15/20234,570,000 shares $98.26 million +22.9%22.7%8.3 $21.50 5/31/20233,720,000 shares $66.74 million +11.0%18.5%6.2 $17.94 5/15/20233,350,000 shares $91.22 million -5.4%16.7%6.5 $27.23 4/30/20233,540,000 shares $72.99 million -5.1%17.7%6.9 $20.62 4/15/20233,730,000 shares $69.90 million +3.6%18.6%7.4 $18.74 3/31/20233,600,000 shares $67.18 million +21.2%18.3%7.2 $18.66 3/15/20232,970,000 shares $58.21 million +5.7%15.1%6.3 $19.60 2/28/20232,810,000 shares $89.70 million +8.9%14.7%8 $31.92 2/15/20232,580,000 shares $84.29 million +5.3%13.5%7.6 $32.67 1/31/20232,450,000 shares $69.87 million +5.6%12.9%7.4 $28.52 1/15/20232,320,000 shares $67.14 million -3.3%12.2%8.1 $28.94 12/30/20222,400,000 shares $51.55 million +10.1%12.6%9.4 $21.48 12/15/20222,180,000 shares $44.04 million -4.4%11.5%9 $20.20 11/30/20222,280,000 shares $37.78 million -3.4%12.0%10.2 $16.57 11/15/20222,360,000 shares $38.00 million -6.7%12.4%10.9 $16.10 10/31/20222,530,000 shares $31.85 million -4.2%13.3%11.7 $12.59 10/15/20222,640,000 shares $27.06 million -5.7%13.9%11.1 $10.25 9/30/20222,800,000 shares $33.10 million -2.1%14.7%10.4 $11.82 9/15/20222,860,000 shares $37.95 million -2.4%15.0%8.5 $13.27 8/31/20222,930,000 shares $40.08 million -0.3%15.4%6.9 $13.68 8/15/20222,940,000 shares $44.86 million +7.7%15.5%6.1 $15.26 7/31/20222,730,000 shares $42.15 million -5.5%14.4%5 $15.44 7/15/20222,890,000 shares $48.70 million -19.7%15.2%5 $16.85 6/30/20223,600,000 shares $47.52 million -9.3%19.0%4 $13.20 6/15/20223,970,000 shares $39.14 million -1.2%20.9%4.4 $9.86 5/31/20224,020,000 shares $47.03 million -2.9%21.2%4.8 $11.70 5/15/20224,140,000 shares $48.60 million +5.3%21.8%5.2 $11.74 4/30/20223,930,000 shares $51.52 million -3.0%20.7%5.3 $13.11 4/15/20224,050,000 shares $63.10 million +97.6%21.4%5.7 $15.58 3/31/20222,050,000 shares $42.87 million +9.0%10.8%3.3 $20.91 3/15/20221,880,000 shares $28.31 million +0.5%9.9%6.1 $15.06 2/28/20221,870,000 shares $34.24 million +10.7%9.9%6.5 $18.31 2/15/20221,690,000 shares $31.38 million -5.1%8.9%5.4 $18.57 1/31/20221,780,000 shares $30.08 million -0.6%9.4%5.5 $16.90 1/15/20221,790,000 shares $34.91 million +3.5%9.4%5.9 $19.50 12/31/20211,730,000 shares $35.17 million -11.7%9.1%5.7 $20.33 12/15/20211,960,000 shares $42.59 million -1.0%10.3%6.7 $21.73 11/30/20211,980,000 shares $45.40 million +10.6%10.4%6.9 $22.93 11/15/20211,790,000 shares $48.71 million -4.3%9.4%6.6 $27.21 10/29/20211,870,000 shares $54.49 million +8.1%9.9%7.5 $29.14 10/15/20211,730,000 shares $46.87 million -6.0%9.1%6.7 $27.09 9/30/20211,840,000 shares $55.84 million -3.2%9.7%6.9 $30.35The mainstream media is wrong about AI — again (Ad)The mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And the media jumped to hasty conclusions. But as usual, there's one huge thing they missed.Click here to learn what everyone else missed. 9/15/20211,900,000 shares $56.51 million -6.9%10.0%5.4 $29.74 8/31/20212,040,000 shares $60.08 million -8.1%10.8%5.4 $29.45 8/13/20212,220,000 shares $54.59 million -5.9%11.8%5.9 $24.59 7/30/20212,360,000 shares $60.39 million -9.9%12.6%6.1 $25.59 7/15/20212,620,000 shares $70.11 million -11.8%14.0%6.8 $26.76 6/30/20212,970,000 shares $86.31 million +2.1%16.9%7.7 $29.06 6/15/20212,910,000 shares $108.60 million -5.5%19.2%7.8 $37.32 5/28/20213,080,000 shares $101.73 million -3.1%20.3%7.8 $33.03 5/14/20213,180,000 shares $96.67 million -5.6%21.0%7.3 $30.40 4/30/20213,370,000 shares $116.27 million -7.7%22.3%7.1 $34.50 4/15/20213,650,000 shares $127.57 million +9.0%N/A7 $34.95 3/31/20213,350,000 shares $137.69 million -9.7%21.4%6.1 $41.10 3/15/20213,710,000 shares $174.33 million +2.8%23.8%6.5 $46.99 2/26/20213,610,000 shares $199.09 million +1.1%23.4%6.7 $55.15 2/12/20213,570,000 shares $230.62 million +5.6%23.1%6.8 $64.60 1/29/20213,380,000 shares $156.33 million -7.9%23.0%6.6 $46.25 1/15/20213,670,000 shares $198.55 million +10.2%25.0%7.7 $54.10 12/31/20203,330,000 shares $163.90 million +4.4%22.7%6.9 $49.22 12/15/20203,190,000 shares $147.89 million -2.5%21.8%7.2 $46.36 11/30/20203,270,000 shares $145.81 million +10.9%22.3%7.2 $44.59 11/15/20202,950,000 shares $160.13 million +4.2%20.1%6.2 $54.28 10/30/20202,830,000 shares $133.15 million +22.0%22.4%5.2 $47.05 10/15/20202,320,000 shares $120.41 million -13.8%18.3%3.5 $51.90 9/30/20202,690,000 shares $116.64 million +17.0%21.3%3.9 $43.36 9/15/20202,300,000 shares $111.09 million +6.5%18.2%3.3 $48.30 8/31/20202,160,000 shares $88.02 million -10.4%17.1%3.1 $40.75 8/14/20202,410,000 shares $90.42 million -14.2%20.7%3.5 $37.52 7/31/20202,810,000 shares $127.46 million +30.1%22.3%4.6 $45.36 7/15/20202,160,000 shares $109.08 million -3.6%20.6%4.3 $50.50 BTAI Short Interest - Frequently Asked Questions What is BioXcel Therapeutics' current short interest? Short interest is the volume of BioXcel Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 317,600 shares of BTAI short. 5.74% of BioXcel Therapeutics' shares are currently sold short. Learn More on BioXcel Therapeutics' current short interest. What is a good short interest ratio for BioXcel Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BTAI shares currently have a short interest ratio of 1.0. Learn More on BioXcel Therapeutics's short interest ratio. What is a good short interest percentage for BioXcel Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.74% of BioXcel Therapeutics' floating shares are currently sold short. Is BioXcel Therapeutics' short interest increasing or decreasing? BioXcel Therapeutics saw a decline in short interest in June. As of June 15th, there was short interest totaling 317,600 shares, a decline of 38.4% from the previous total of 515,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is BioXcel Therapeutics' float size? BioXcel Therapeutics currently has issued a total of 6,060,000 shares. Some of BioXcel Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. BioXcel Therapeutics currently has a public float of 5,530,000 shares. How does BioXcel Therapeutics' short interest compare to its competitors? 5.74% of BioXcel Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to BioXcel Therapeutics: Alterity Therapeutics Limited - Sponsored ADR (0.81%), Iterum Therapeutics PLC (2.99%), Karyopharm Therapeutics Inc. (25.38%), Akari Therapeutics PLC (0.11%), Acrivon Therapeutics, Inc. (5.05%), Clene Inc. (6.01%), Vor Biopharma Inc. (4.19%), Eagle Pharmaceuticals, Inc. (0.46%), Barinthus Biotherapeutics PLC Sponsored ADR (0.09%), LAVA Therapeutics N.V. (0.50%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short BioXcel Therapeutics stock? Short selling BTAI is an investing strategy that aims to generate trading profit from BioXcel Therapeutics as its price is falling. BTAI shares are trading up $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BioXcel Therapeutics? A short squeeze for BioXcel Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BTAI, which in turn drives the price of the stock up even further. How often is BioXcel Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BTAI, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies ATHE Short Squeeze ITRM Short Squeeze KPTI Short Squeeze AKTX Short Squeeze ACRV Short Squeeze CLNN Short Squeeze VOR Short Squeeze EGRX Short Squeeze BRNS Short Squeeze LVTX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BTAI) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
